Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep, Updated Plan Follows PanCAN's Re-Evaluation Of Precision Promise Program

Author: Benzinga Newsdesk | November 09, 2023 07:35am

Oncolytics and its collaborator, The Pancreatic Cancer Action Network (PanCAN), had previously planned to initiate a Phase 3 trial using the Precision Promise platform in H1 2024. Oncolytics now plans to conduct an adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study and manage it directly within our Clinical Group and a contract research organization with the goal of enrolling the first patient in mid-2024.

Posted In: ONCY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist